
Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS
Natalizumab-sztn (Tyruko; Sandoz) expressed efficacy and safety in patients with relapsing-remitting multiple sclerosis (RRMS) to confirm matching immunogenicity profiles between the biosimilar and reference natalizumab (Tysabri; Biogen), according to a …